Mizner Bioscience LLC reported on Wednesday the receipt of the first approval for a therapeutically equivalent generic version of Clomipramine Hydrochloride Tablets from the US Food and Drug Administration's (FDA) Abbreviated New Animal Drug Application (ANADA) pathway.
Clomipramine Hydrochloride Tablets are used as part of a comprehensive behavioural management programme to treat separation anxiety in dogs over six months of age.
Following the FDA's approval, the company will launch its Clomipramine Hydrochloride Tablets in 5mg, 20mg, 40mg and 80mg with immediate effect.
According to the company, the tablet is the equivalent generic version of Elanco's Clomicalm (Clomipramine Hydrochloride Tablets).
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling